Ardelyx Inc. (ARDX)
5.03
0.18 (3.71%)
At close: Apr 24, 2025, 12:12 PM
3.71% (1D)
| Bid | 5.02 |
| Market Cap | 1.2B |
| Revenue (ttm) | 333.62M |
| Net Income (ttm) | -39.14M |
| EPS (ttm) | -0.17 |
| PE Ratio (ttm) | -29.56 |
| Forward PE | 19.22 |
| Analyst | Buy |
| Ask | 5.03 |
| Volume | 1,532,956 |
| Avg. Volume (20D) | 4,230,880 |
| Open | 4.85 |
| Previous Close | 4.85 |
| Day's Range | 4.80 - 5.03 |
| 52-Week Range | 4.02 - 9.33 |
| Beta | 0.81 |
About ARDX
Ardelyx, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat gastrointestinal and cardiorenal therapeutic areas in the United States and internationally. The company's lead product candidate is tenapanor, which has completed Phase III clinical trial for the treatment of patients with irritable bowel syndrome with constipation, as well as in Phase III clinical trial to control serum phosphorus in adult pat...
Industry Biotechnology
Sector Healthcare
IPO Date Jun 19, 2014
Employees 395
Stock Exchange NASDAQ
Ticker Symbol ARDX
Website https://www.ardelyx.com
Analyst Forecast
According to 9 analyst ratings, the average rating for ARDX stock is "Buy." The 12-month stock price forecast is $10.5, which is an increase of 108.96% from the latest price.
Stock ForecastsNext Earnings Release
Ardelyx Inc. is scheduled to release its earnings on May 1, 2025,
after market closes.
Analysts project revenue of ... Unlock content with Pro Subscription
Analysts project revenue of ... Unlock content with Pro Subscription
2 months ago
-11.54%
Ardelyx shares are trading lower after Raymond Jam...
Unlock content with
Pro Subscription
2 months ago
-10.06%
Ardelyx shares are trading lower. The company reported Q4 financial results.
